Additional safety and exploratory efficacy data at 48 and 60 months from Open-HART, an open-label extension study of pridopidine in Huntington disease

McGarry A, Auinger P, Kieburtz K, et al. J Huntingtons Dis. 2020;9(2):173-184. doi:10.3233/JHD-190393